Abstract:Glucagon is generally considered to be a counter-regulatory hormone with a primary role to raise blood glucose concentrations by increasing endogenous glucose production (EGP). However, recent preclinical findings support a paracrine action of glucagon to act directly on pancreatic beta cells to promote nutrient-stimulated insulin secretion. In mice, the divergent actions of glucagon are dependent on glycemic status: during fasting glucagon acts predominantly at the liver to raise blood glucose, whereas in the fed state when glycemia is elevated, the insulinotropic effects predominate to lower glucose. These mechanistic findings have not been extended to human physiology. Therefore, we designed a study to test the hypothesis that in healthy humans glucagon actions are also dependent on ambient glycemia. Subjects received glucagon (100 ng/kg) during fasting euglyemia or experimental hyperglycemia (~150 mg/dl) on separate days. On both days, glycemia was maintained for 60 min prior to a glucagon infusion for an additional 60 min. Blood glucose was monitored at bedside and plasma samples were analyzed for C-peptide and di-deuterated glucose enrichment to calculate HGP. During fasting euglycemia, blood glucose was 85 mg/dl and glucagon elicited an increase to a 60 minute average of 132 mg/dl with a peak at ~156 mg/dl at the end of the infusion. Concordant with increased glycemia was an immediate increase in HGP (1.8x) and a delayed increase in C-peptide AUC (1.5x). For the hyperglycemia studies, blood glucose was maintained at 150 mg/dl before and during glucagon administration. Here, glucagon caused a rapid and robust increase in C-peptide AUC (4x) and a more gradual increase in HGP (2x). This glycemic-dependent behavior of glucagon suggests a physiologic role to promote prandial insulin secretion in healthy subjects. This raises the possibility that this incretin function of glucagon plays a role in β-cell function in diabetic subjects. Disclosure S. M. Gray: None. G. Zhang: None. W. Bennett: None. J. Tong: None. J. Campbell: None. D. A. D’alessio: Advisory Panel; Self; Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Research Support; Self; Eli Lilly and Company, Merck & Co., Inc. Funding National Institutes of Health (F32DK121420, R01DK101991)

Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes

Advances in the clinical measurement of glucagon: from diagnosis to therapy

The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

Glucagon 100 years. Important, but still enigmatic.

Glucagon and Regulation of Glucose Metabolism

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Hepatic Glucagon Action - Beyond Glucose Mobilization

Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Glucagon Receptor Signaling and Lipid Metabolism

Glucagon in type 2 diabetes: Friend or foe?

Glucagon, from past to present: a century of intensive research and controversies

198-OR: The Stimulatory Effect of Glucagon on Insulin Secretion Is Glucose Dependent in Healthy Human Subjects

[Glucagon and glucagon-like peptides the role in control glucose homeostasis. Part I]

Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes

Glucagon secretion and signaling in the development of diabetes

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

Glucagon-like peptide-1 and its receptors and their fuctions in the treatment of type 2 diabetes mellitus

High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans

Mechanisms by Which Glucagon Acutely Stimulates Hepatic Mitochondrial Oxidation and Gluconeogenesis

Role of intestinal glucagon-like peptide-1 in impaired counter-regulatory responses to hypoglycemia

The physiology of glucagon-like peptide 1